MAPT and Alzheimer disease: Recently, in a longitudinal study (4, 8, 12, and 16 months of age) using a mouse model of AD, 3×Tg-AD, we reported that this model presents, since the early time points, (i) recognition memory impairment, (ii) increased levels of Aβ and hyperphosphorylated tau in the hippocampus, (iii) decreased hippocampal volume, and (iv) loss of taurine, which is an important endogenous neuroprotector.